NUCLEOLIN and cancer: Among these, we found interactions that may constitute potential targets for CAFs-based therapies, such as THBS2/THBS3 (myCAF2) and CD47 (cancer cells) or between MDK (CAFs) and SDC2/SDC4/NCL (cancer cells) (Fig. 5A).